Commodity Channel Index
Previous Close | 126.47 |
Open | 128.49 |
Bid | 126.05 x 900 |
Ask | 126.45 x 1100 |
Day's Range | 124.25 - 128.49 |
52 Week Range | 115.03 - 217.25 |
Volume | |
Avg. Volume | 3,446,948 |
Market Cap | 48.124B |
Beta (5Y Monthly) | 1.69 |
PE Ratio (TTM) | 11.22 |
EPS (TTM) | 11.25 |
Earnings Date | Aug 01, 2023 - Aug 07, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 218.80 |
Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S.
U.S. vaccine maker Moderna said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy. The U.S. pharmaceutical and biotech firm registered a unit called Moderna (China) Biotech Limited in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha. "We are exploring opportunities to engage in the market and bring the power of Moderna’s mRNA platform to the people of China," a spokesperson said in response to a query from Reuters.
BEIJING (Reuters) -Vaccine maker Moderna Inc said on Friday it was looking for opportunities in China after confirming that it had registered a legal entity in the world's second largest economy. The U.S. biotech firm registered a unit called Moderna (China) Biotech Ltd in Shanghai on May. 24 with capital of $100 million, according to Chinese data providers including company database Qichacha. "We are exploring opportunities to engage in the market and bring the power of Moderna's mRNA platform to the people of China," a company spokesperson said in response to a query from Reuters.
Three years since the pandemic upended the economy, here are the Massachusetts public companies that made it through in the best — and worst — shape.
Is Moderna stock a buy after the company reported a 19-cent gain in the first quarter vs. calls for losses? Is MRNA stock a buy?
The fact that multiple Moderna, Inc. ( NASDAQ:MRNA ) insiders offloaded a considerable amount of shares over the past...
Insider buying, or the legal, reported purchase of shares in a company by its C-suite/board members/large shareholders, is considered a bullish signal. However, does that mean it is best to sell/avoid stocks insiders are selling? Put simply, it depends. Heavy insider selling, or even a lack of insider buying, can sometimes be a sign that those most “in the know” at a company are not very confident in its future prospects. Then again, much like with “outsider” investors, lack of confidence isn’t
A life sciences company in Durham has secured a major partnership to discover new gene therapy treatments.
The Moving Average Convergence Divergence (MACD) oscillator is below the zero line telling us that MRNA lacks trend strength. In this daily Point and Figure chart of MRNA, below, I can see a potential upside price target in the $179 area. This weekly Point and Figure chart of MRNA, below, shows us the same $179 price target as the daily chart above.
Yahoo Finance Live discusses a drop in shares of Moderna after a report of a resurgence of Covid in China.
Biotech giant Moderna (NASDAQ: MRNA) made a name for itself in the past couple of years as it developed and marketed one of the most successful coronavirus vaccines. Demand for coronavirus vaccines has started to fall, affecting Moderna's revenue. Is Moderna's stock worth considering, especially at current levels?
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The good news is you really don't have to -- and you still can win in the stock market. The success of Moderna's (NASDAQ: MRNA) blockbuster coronavirus vaccine helped the stock soar earlier in the pandemic. Here's why they shouldn't: The vaccine represents just the beginning of Moderna's growth story.
Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.
These biotech stocks are swinging for the fences. They may hit homers, they may strike out. But you’ll definitely want to watch them. Biotech stocks have been a high risk, high reward proposition in recent years. Many biotech companies soared high during the pandemic only to crash hard in its aftermath. We now search through the wreckage to see which will soar again, and which are best left for dead. For an investor who wants stability and low risk, there are plenty of big biotech stocks out the
Biotech investors love to take on oodles of risk in hopes of getting an outsized reward when one of their bets finally pays off. While NHPs account for only 0.5% of the animal models used in biomedicine, biotechs and other researchers in the U.S. have faced a shortage of NHPs since at least 2019.
Moderna,Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, reported on interim data from the Phase 1/2 trial of mRNA-3927, an investigational mRNA therapy for propionic acidemia (PA), presented at the 2023 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting.
Moderna (NASDAQ: MRNA) surprised investors last quarter when it didn't incur a loss despite a significant drop in sales. For the first three months of 2023, Moderna's revenue totaled just under $1.9 billion, which is just a fraction of the $6.1 billion it reported in the same period last year. Meanwhile, its operating expenses, totaling $2.2 billion, rose by more than 21%.
It's never too early to start building a portfolio that may eventually make you a millionaire. Today, many growth stocks are suffering, but in some cases, prospects over time remain bright. Amazon (NASDAQ: AMZN) was on an earnings roll, delivering gains in net income year after year -- until last year, when the company swung to a loss for the first time since 2014.
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here. The first quarter was difficult for the fund, as it failed to participate in the broader market rally and declined 3.69% compared to the 3.27% decline for the benchmark Russell […]
Moderna (NASDAQ: MRNA) saw its shares jump in 2021 and 2022 on the back of strong sales of its COVID-19 vaccine Spikevax. Spikevax helped prove to the world the effectiveness of messenger RNA (mRNA) technology. The company advanced three COVID-19 vaccines from phase 1 to commercial status in a year.
Moderna (NASDAQ: MRNA) started its billion-dollar story with the coronavirus vaccine. The company plans to submit its candidate for use in older adults to regulators soon and aims for a 2024 launch. The U.S. Food and Drug Administration (FDA) recently approved GSK's vaccine -- the first RSV vaccine to ever win a nod.
Flagship Pioneering, the bioplatform innovation company, today announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics. Two years into development, Flagship has made an initial commitment of $50 million to advance Metaphore's MIMiC™ platform and build its pipeline for patients with autoimmune, metabolic, or oncology indications.
Key Insights The projected fair value for Moderna is US$241 based on 2 Stage Free Cash Flow to Equity Moderna is...
On May 9, Novavax (NASDAQ: NVAX) shareholders got a much-needed reprieve from the stock's downward trajectory over the last year. Novavax's decline is a regrettable one. Its coronavirus vaccine candidate ran into regulatory issues during clinical development, and arrived on the market much later than those of competitors like Pfizer and Moderna.